Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Parts A and B~Inclusion Criteria:~* Diagnosis of AIP~* Urine PBG at Screening indicating patient is a high excreter~* No clinically significant health concerns~* Women of child bearing potential must have a negative pregnancy test, not be nursing, and use effective contraception~* Willing to provide written informed consent and willing to comply with study requirements.~Exclusion Criteria:~* Porphyria attack within 6 months of screening~* Started a new prescription medication within 3 months of screening~* Clinically significant abnormal laboratory results~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection~Part C~Inclusion Criteria:~* Diagnosis of AIP~* Patient experienced a porphyria attack or was taking medication to prevent attacks recently~* No clinically significant health concerns~* Women of child bearing potential must have a negative pregnancy test, not be nursing, and use effective contraception~* Willing to provide written informed consent and willing to comply with study requirements.~Exclusion Criteria:~* Stared a new prescription medication within 3 months of screening~* Clinically significant abnormal laboratory results~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- givosiran (ALN-AS1) (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).